GlaxoSmithKline (GSK +0.4%) says it's submitted a regulatory application in the European Union...

|About: GlaxoSmithKline (GSK)|By:, SA News Editor

GlaxoSmithKline (GSK +0.4%) says it's submitted a regulatory application in the European Union for umeclidinium bromide, or UMEC, an investigational once-daily medicine for patients with chronic obstructive pulmonary disease. Regulatory filings are pending in the U.S. and planned for other countries during the course of 2013.